MNPR (Monopar Therapeutics) Other Long-Term Liabilities: $-0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MNPR Monopar Therapeutics Inc MNPR
33 GF Score
Price $110.41
! 3 Warning Signs
View Full Analysis

What is Monopar Therapeutics Other Long-Term Liabilities?

Monopar Therapeutics MNPR -3.48% 33 Other Long-Term Liabilities is $-0.00 Mil as of Jun. 2026. GuruFocus rates MNPR with a GF Score™ of 33/100. The stock has 3 warning signs investors should review.

Monopar Therapeutics's other long-term liabilities for the quarter that ended in Jun. 2026 was $-0.00 Mil.

Monopar Therapeutics's quarterly other long-term liabilities declined from Dec. 2025 ($0.00 Mil) to Mar. 2026 ($-0.00 Mil) but then increased from Mar. 2026 ($-0.00 Mil) to Jun. 2026 ($-0.00 Mil).

Monopar Therapeutics's annual other long-term liabilities stayed the same from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($0.00 Mil) but then increased from Dec. 2024 ($0.00 Mil) to Dec. 2025 ($0.00 Mil).

Monopar Therapeutics Other Long-Term Liabilities Related Terms

Monopar Therapeutics Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Monopar Therapeutics's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Monopar Therapeutics Other Long-Term Liabilities Chart

Monopar Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Monopar Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.00 -0.00 0.00 -0.00 -0.00
MNPR
33GF Score
Monopar Therapeutics Inc MNPR
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Monopar Therapeutics Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of $-0.00 Mil mean?
Monopar Therapeutics (MNPR) has a Other Long-Term Liabilities of $-0.00 Mil as of Jun. 2026. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Monopar Therapeutics and its competitors.
Is Monopar Therapeutics' Other Long-Term Liabilities too high?
Monopar Therapeutics' current Other Long-Term Liabilities is $-0.00 Mil. Overall, Monopar Therapeutics has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Monopar Therapeutics' Other Long-Term Liabilities compare to DSGN and CLYM?
Monopar Therapeutics' Other Long-Term Liabilities of $-0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Biotechnology company?
A good Other Long-Term Liabilities depends on the Biotechnology industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Monopar Therapeutics and its competitors. Monopar Therapeutics's current Other Long-Term Liabilities is $-0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Monopar Therapeutics stock overvalued right now?
Monopar Therapeutics (MNPR) has a current Other Long-Term Liabilities of $-0.00 Mil. The current Other Long-Term Liabilities is $-0.00 Mil. Monopar Therapeutics' overall GF Score™ is 33/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Monopar Therapeutics (MNPR), the current Other Long-Term Liabilities is $-0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Monopar Therapeutics Business Description

Other Exchanges 1IY0:Germany
Address 1000 Skokie Boulevard, Suite 350, Wilmette, IL, USA, 60091
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.
33GF Score

Get the complete analysis for MNPR

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$110.41
Price